IAVI
Translating scientific discoveries into affordable, accessible public health solutions
Programs and results
What we aim to solve
Our programs
What are the organization's current programs, how do they measure success, and who do the programs serve?
Discovery
IAVI’s vaccine discovery and development laboratories are focused on identifying ways to generate protective immune responses against HIV and other infectious diseases, characterizing and optimizing antibodies as prevention and treatment products, and addressing other unmet global health needs. In doing this wide-ranging work, IAVI researchers collaborate closely with other innovators across the global health research landscape.
In 2008, IAVI established the Vaccine Design and Development Laboratory (DDL) to facilitate the design and development of viral vectors for vaccines. Scientists at the DDL engineer natural viruses to deliver vaccine immunogens with the goal of generating long-lasting antiviral immune responses. The DDL team uses the vesicular stomatitis virus (VSV) as a vector to develop vaccine candidates for HIV and emerging infectious diseases such as Lassa fever, Marburg virus diseases, and COVID-19.
Since 2009, due to the efforts of the IAVI Neutralizing Antibody Center (NAC) at Scripps Research and other institutions, hundreds of broadly neutralizing antibodies (bnAbs) have been isolated from volunteers with HIV. The structures of some of the most potent of these antibodies and their targets on the virus have also been solved. NAC scientists are now using these discoveries to inform the design of novel HIV vaccine candidates and are using advances in antibody science to develop antibodies to prevent and treat other diseases.
The HIV Vaccine Translational Research (HVTR) Laboratory at the Translational Health Science and Technology Institute (THSTI) NCR Biotech Science Cluster in Faridabad, Haryana, India, designs and evaluates preventive HIV vaccines. As a NAC-collaborating center of excellence, the laboratory plays a crucial role in spurring indigenous antibody discovery and preclinical development efforts and promoting industry collaboration on promising prevention products.
The IAVI Human Immunology Laboratory (HIL), based at Imperial College London, serves as the clinical immunology reference laboratory for IAVI and its research partners worldwide. The HIL specializes in the analysis of immune responses from studies and clinical trials by IAVI and its partners, serves as a central repository for samples collected from clinical and epidemiology research studies, and plays a crucial role in strengthening existing scientific capabilities in affiliated African and Indian laboratories.
Translation & Product Development
IAVI develops vaccine candidates and other biomedical innovations and manages clinical research with partners in academic, biotechnology, pharmaceutical, and government institutions. IAVI also provides translational research services and support to other organizations in the field, assisting them with the complex process of transitioning innovations from the laboratory into clinical trials. This includes providing assistance with manufacturing protocols and clinical and regulatory filings.
Product Development Center
In 2013, the Bill & Melinda Gates Foundation (BMGF) awarded a grant to IAVI to create the Vaccine Product Development Center (VxPDC) to assist investigators affiliated with BMGF’s Collaboration for AIDS Vaccine Discovery with the complex process of transitioning vaccine candidates from the laboratory to the clinic. Subsequently, IAVI expanded the Product Development Center (PDC) in recognition of efforts beyond vaccines and extending this translational expertise to other partners — whether academic, nonprofit, government, or industry — that are advancing new biomedical interventions. The PDC fills a critical gap in the development process for new vaccines and other biomedical innovations. Today, investigators from the U.S. National Institutes of Health and European funding partners are among those who utilize IAVI’s PDC.
The PDC provides:
- A team of pharmaceutical development experts who collectively have advanced hundreds of projects through global regulatory agencies.
- An extensive network of Contract Research Organizations, Contract Manufacturing Organizations, and technology partners to accelerate development and minimize risk.
- Access to clinical research networks around the world, including in Africa and India.
- Over 20 years of HIV vaccine development experience from projects using a wide range of technology platforms.
Clinical and Epidemiology Research
IAVI conducts clinical trials, observational epidemiology, and socio-behavioral research that informs the design of vaccine candidates and other prevention modalities. This work also provides important data for future efficacy trials to prevent HIV and other diseases of global public health significance. IAVI works with academic, government, foundation, and community-based partners to conduct this research.
IAVI’s network of clinical research partners in sub-Saharan Africa, India, and the U.K. play a central role in our clinical research.
IAVI supports the development of in-country scientific and technical expertise and leadership needed to conduct research at the highest ethical and scientific standards. IAVI also implements the concepts of Good Participatory Practice Guidelines to ensure community engagement throughout the research process.
IAVI’s key clinical research activities:
- Test novel vaccines and antibodies from preclinical research through Phase I-III clinical trials. This includes products against HIV, SARS-CoV2, tuberculosis, Lassa fever, snakebite, and others.
- Prepare to execute efficacy trials in at-risk populations through supportive epidemiology and capacity building, as well as stakeholder and community engagement.
- Develop in-country scientific capacity and leadership in the HIV research field, including HIV vaccine design and development through a wide range of collaborative and education programs.
Global Community Engagement
IAVI advocacy work engages policymakers, scientists, activists, civil society organizations, influencers, community representatives, and stakeholders across the world to ensure that necessary resources and policies can sustain local, regional, and global support for vaccine development and new biomedical prevention approaches. IAVI recognizes that these approaches must reflect regional realities and priorities essential to ending AIDS, tuberculosis (TB), and emerging infectious diseases (EIDs) as well as addressing other unmet global health challenges. IAVI’s advocacy partners — from the community to the global level — mobilize a comprehensive response to disease prevention while ensuring decision-makers have the information and evidence to make informed choices about supporting global health solutions. This work has forged the path for HIV vaccines to be listed as national health research priorities in many countries where the organization works. IAVI, in partnership with the Uganda AIDS Commission, has also developed guidelines and a road map for delivering HIV and AIDS services in vulnerable Ugandan fishing communities. These national commitments translate into increased domestic support for strengthening research and regulatory facilities, as well as inclusive and effective health policies.
IAVI’s careful and informed approach to community engagement is essential to conduct safe and ethical HIV, TB and EID research in a way that avoids the potential for social harm such as discrimination, gender-based violence and stigma to study participants, especially those most vulnerable, including adolescent women and young girls, men who have sex with men, transgender women, and fishing communities. The IAVI model for community engagement continues to demonstrate that many marginalized and vulnerable communities are accessible and, with careful outreach initiatives, are eager to participate in potentially lifesaving scientific research. Activities such as India’s experiential learning, interactive theatre, and creative arts-based approaches demystify clinical trials for potential participants. Such work is essential for ensuring a fully informed and balanced representation of key populations in clinical trials.
Where we work
External reviews

Videos
Our results
How does this organization measure their results? It's a hard question but an important one.
Epidemiology studies conducted that informed the design of HIV vaccine efficacy trials, improving future accessibility and acceptability of final product
This metric is no longer tracked.Totals By Year
Population(s) Served
People with HIV/AIDS
Related Program
Discovery
Type of Metric
Output - describing our activities and reach
Direction of Success
Increasing
IAVI-sponsored replicating VSV vector candidates advanced in novel portfolio toward clinical development
This metric is no longer tracked.Totals By Year
Population(s) Served
People with diseases and illnesses
Related Program
Discovery
Type of Metric
Output - describing our activities and reach
Direction of Success
Increasing
Clinical research partners in Africa and India, including 11 state-of-the-art clinical research center partners with 12 GCLP-accredited laboratories capable of conducting clinical research at international standards.
This metric is no longer tracked.Totals By Year
Population(s) Served
People with diseases and illnesses
Related Program
Discovery
Type of Metric
Output - describing our activities and reach
Direction of Success
Increasing
Scientists in LMICs trained in GCP and GCLP to international standards for conducting clinical trials
This metric is no longer tracked.Totals By Year
Population(s) Served
People with diseases and illnesses
Type of Metric
Output - describing our activities and reach
Direction of Success
Increasing
National and regional policies included HIV vaccine research, resulting in enhanced local ownership and an improved environment for research with at-risk populations.
This metric is no longer tracked.Totals By Year
Population(s) Served
People with diseases and illnesses
Related Program
Discovery
Type of Metric
Output - describing our activities and reach
Direction of Success
Increasing
Projects managed by the IAVI Product Development Center since its establishment in 2013, as an integrated platform to advance promising concepts from bench to clinic
This metric is no longer tracked.Totals By Year
Population(s) Served
People with diseases and illnesses
Related Program
Discovery
Type of Metric
Outcome - describing the effects on people or issues
Direction of Success
Increasing
Phase I/II trials supported by IAVI’s Product Development Center to assess external vaccine candidates and biologics.
This metric is no longer tracked.Totals By Year
Population(s) Served
People with diseases and illnesses
Related Program
Discovery
Type of Metric
Outcome - describing the effects on people or issues
Direction of Success
Increasing
Number of research or policy analysis products developed, e.g., reports, briefs
This metric is no longer tracked.Totals By Year
Population(s) Served
Adolescents, Young adults, People with diseases and illnesses
Related Program
Discovery
Type of Metric
Outcome - describing the effects on people or issues
Direction of Success
Holding steady
Context Notes
Scientific papers published by IAVI and partners
Number of media citations of advocate research or products
This metric is no longer tracked.Totals By Year
Population(s) Served
People with diseases and illnesses
Related Program
Discovery
Type of Metric
Outcome - describing the effects on people or issues
Direction of Success
Increasing
Context Notes
Includes social media
Evidence demonstrating impact of research on gender, equity and the most vulnerable (through case studies)
This metric is no longer tracked.Totals By Year
Population(s) Served
People with HIV/AIDS
Related Program
Discovery
Type of Metric
Outcome - describing the effects on people or issues
Direction of Success
Holding steady
Context Notes
Number of other open access, quality assured knowledge products produced and disseminated (e.g.,
Value of co-funding for IAVI programmes leveraged from nongovernment sources
This metric is no longer tracked.Totals By Year
Population(s) Served
People with diseases and illnesses
Related Program
Discovery
Type of Metric
Outcome - describing the effects on people or issues
Direction of Success
Decreasing
Context Notes
Estimated total - HIV only.
Goals & Strategy
Reports and documents
Download strategic planFinancials
Unlock nonprofit financial insights that will help you make more informed decisions. Try our monthly plan today.
- Analyze a variety of pre-calculated financial metrics
- Access beautifully interactive analysis and comparison tools
- Compare nonprofit financials to similar organizations
Want to see how you can enhance your nonprofit research and unlock more insights?
Learn more
about GuideStar Pro.
Operations
The people, governance practices, and partners that make the organization tick.
Connect with nonprofit leaders
SubscribeBuild relationships with key people who manage and lead nonprofit organizations with GuideStar Pro. Try a low commitment monthly plan today.
- Analyze a variety of pre-calculated financial metrics
- Access beautifully interactive analysis and comparison tools
- Compare nonprofit financials to similar organizations
Want to see how you can enhance your nonprofit research and unlock more insights? Learn More about GuideStar Pro.
Connect with nonprofit leaders
SubscribeBuild relationships with key people who manage and lead nonprofit organizations with GuideStar Pro. Try a low commitment monthly plan today.
- Analyze a variety of pre-calculated financial metrics
- Access beautifully interactive analysis and comparison tools
- Compare nonprofit financials to similar organizations
Want to see how you can enhance your nonprofit research and unlock more insights? Learn More about GuideStar Pro.
IAVI
Board of directorsas of 8/17/2021
Dr. Eric Goosby
University of California, San Francisco
Anne VanLent
AMV Advisors
Anne VanLent
President, AMV Advisors
Marijke Wijnroks
Chief of Staff, The Global Fund to Fight AIDS, Tuberculosis and Malaria
Linda-Gail Bekker
Deputy Director, Desmond Tutu HIV Centre
David Blumberg
Vice President, Teva Global Operations and Portfolio Compliance, Teva Pharmaceuticals
Jim Connolly
Former President and CEO of Aeras
Mark Dybul
Faculty Co-Director of the Center for Global Health Quality and Professor in the Department of Medicine, Georgetown University Medical Center
Robert Goldberg
Chief Operating Officer, Barnard College
Eric Goosby
Director, Center for Implementation Sciences, Global Health Sciences, at the University of California, San Francisco
John Nkengasong
Director, Africa Centres for Disease Control and Prevention
Francine Ntoumi
Research Group Leader, Institute for Tropical Medicine, University of Tübingen
John Shiver
Senior Vice President of Global Vaccine R&D, Sanofi Pasteur
Anne Simonds
Board/CEO Leadership Adviser, Global Leader of Health, Development and Social Enterprise, Spencer Stuart
Rajeev Venkayya
President, Global Vaccine Business Unit, Takeda Pharmaceuticals
Board leadership practices
GuideStar worked with BoardSource, the national leader in nonprofit board leadership and governance, to create this section.
-
Board orientation and education
Does the board conduct a formal orientation for new board members and require all board members to sign a written agreement regarding their roles, responsibilities, and expectations? Yes -
CEO oversight
Has the board conducted a formal, written assessment of the chief executive within the past year ? Yes -
Ethics and transparency
Have the board and senior staff reviewed the conflict-of-interest policy and completed and signed disclosure statements in the past year? Yes -
Board composition
Does the board ensure an inclusive board member recruitment process that results in diversity of thought and leadership? Yes -
Board performance
Has the board conducted a formal, written self-assessment of its performance within the past three years? No
Organizational demographics
Who works and leads organizations that serve our diverse communities? GuideStar partnered on this section with CHANGE Philanthropy and Equity in the Center.
Leadership
The organization's leader identifies as:
The organization's co-leader identifies as:
Race & ethnicity
No data
Gender identity
No data
No data
Sexual orientation
No data
Disability
No data